Table 2 Breast Cancer diagnosis and ParaDNA feasibility in African setting
Questionnaire | Number(N) = 50 | Percentage (%) |
|---|---|---|
Knowledge on diagnosis of BC | ||
Sanger sequencing Microscopy/histology Nanopore sequencing BRCA1/2 MammaPrint Breast ultrasound Mammogram/MRI TaqMan genotyping | 20/50 37/50 24/50 5/50 15/50 22/50 4/50 | 40% 74% 48% 10% 30% 44% 8% |
Knowledge on ParaDNA genotyping | ||
Benefit of ParaDNA/Sanger Identification of BRCA1/2 Prediction of CVD/comorbidities Turnaround within 75 min Easy to perform Can be cost effective/Sanger Automated DNA extraction, PCR and sequencing Can be used by non-specialized person | 21/50 20/50 6/50 16/50 15/50 5/50 7/50 25/50 | 42% 40% 12% 32% 30% 10% 14% 50% |
Barriers to ParaDNA implementation | ||
Limited accessibility Knowledge gaps Governance issues Lack of molecular lab for cancers Lack of trainings and awareness Lack of policy on point of care genetic testing’s Ethics and law regarding genetic testing’s | 2/50 33/50 23/50 11/50 20/50 20/50 8/50 | 4% 66% 46% 22% 40% 40% 16% |
Application of POCT in diagnostic of COVID-19 | ||
Yes No | 21/50 29/50 | 42% 68% |
Recommendations | ||
Training and equipment Providing molecular lab and devices | 11/50 39/50 | 22% 78% |